Aims We investigated the role of src family kinases (srcFK) in agonist-mediated Ca 2þ -sensitization in pulmonary artery and whether this involves interaction with the rho/rho-kinase pathway. Methods and results Intra-pulmonary arteries (IPAs) and cultured pulmonary artery smooth muscle cells (PASMC) were obtained from rat. Expression of srcFK was determined at the mRNA and protein levels. Ca 2þ -sensitization was induced by prostaglandin F 2a (PGF 2a ) in a-toxin-permeabilized IPAs. Phosphorylation of the regulatory subunit of myosin phosphatase (MYPT-1) and of myosin light-chain-20 (MLC 20 ) and translocation of rho-kinase in response to PGF 2a were also determined. Nine srcFK were expressed at the mRNA level, including src, fyn, and yes, and PGF 2a enhanced phosphorylation of three srcFK proteins at tyr-416. In a-toxin-permeabilized IPAs, PGF 2a enhanced the Ca 2þ -induced contraction (pCa 6.9) approximately three-fold. This enhancement was inhibited by the srcFK blockers SU6656 and PP2 and by the rho-kinase inhibitor Y27632. Y27632, but not SU6656 or PP2, also inhibited the underlying pCa 6.9 contraction. PGF 2a enhanced phosphorylation of MYPT-1 at thr-697 and thr-855 and of MLC 20 at ser-19. This enhancement, but not the underlying basal phosphorylation, was inhibited by SU6656. Y27632 suppressed both basal and PGF 2a -mediated phosphorylation. The effects of SU6656 and Y27632, on both contraction and MYPT-1 and MLC 20 phosphorylation, were not additive. PGF 2a triggered translocation of rho-kinase in PASMC, and this was inhibited by SU6656. Conclusions srcFK are activated by PGF 2a in the rat pulmonary artery and may contribute to Ca 2þ -sensitization and contraction via rho-kinase translocation and phosphorylation of MYPT-1.
Introduction
Ca 2þ -sensitization in smooth muscle is the process by which increased myosin light-chain phosphorylation, and hence contractile force, occurs, generated in response to an external stimulus independently of changes in intracellular Ca 2þ concentration ([Ca 2þ ] i ). 1 In smooth muscle, this is believed to occur principally through phosphorylation of myosinbinding subunit (or MYPT-1) and subsequent inhibition of myosin light-chain phosphatase. 2 MYPT-1 is phosphorylated by rho-kinase at two sites (thr-697 and thr-855 in rat), the first of which results in inhibition of phosphatase activity 3 and the second results in dissociation of the phosphatase from myosin. 4 Rho-kinase is activated by binding to the GTP-bound form of the small G-protein RhoA and subsequent translocation. 5 The mechanisms by which agonist stimulation activates RhoA are not fully understood, but the involvement of guanine nucleotide exchange factors (RhoGEF) is a requirement. 6 src family kinases (srcFK) are a group of closely related non-receptor tyrosine kinases, the eponymous member of which has been found to be highly expressed in vascular tissues. 7 srcFK are activated by myristoylation and/or palmitoylation, 8 translocation to the plasma membrane, 9 and subsequent auto-phosphorylation at tyr-416. 10 Tyrosine kinases in general are implicated in vascular smooth muscle contraction, both via actions upon Ca 2þ release and/or influx and via Ca 2þ -sensitization. [11] [12] [13] [14] [15] Although evidence for the latter is somewhat contradictory, 11, 14 one study clearly shows that sphingosylphosphorylcholine-mediated contraction and translocation of rho-kinase in pig coronary artery are dependent on srcFK. 16 srcFK may regulate rho activation via phosphorylation of RhoGEF. 6 Ca 2þ -sensitization and the rho/rho-kinase pathway are important components of contractile function in pulmonary artery, in response to agonists and acute or chronic hypoxia, both in normal and patho-physiological settings, 17, 18 whereas the role(s) of srcFK are largely unexplored. 19 In the present study, therefore, we evaluated the role of srcFK in Ca 2þ -sensitization-dependent prostaglandin F 2a (PGF 2a )-mediated contraction in rat small distal pulmonary arteries and srcFK interaction with the rho/rho-kinase pathway.
Methods

Animals, tissue isolation, and cell culture
This study conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Male Wistar rats (200-250 g) were killed by lethal overdose of pentobarbital (ip). Lungs were excised and placed in cold physiological salt solution (PSS), and first to third-order branches of the intra-pulmonary artery (IPA) were dissected free of surrounding parenchyma. First, second, and third-order branches (150-1000 mm diameter) were used for the extraction of mRNA for polymerase chain reaction (PCR) and protein for western blot experiments. Second or third-order branches (150-600 mm diameter) were used for the preparation of pulmonary artery smooth muscle cells (PASMC) and measurement of isometric tension.
PASMC were dispersed enzymatically and grown in DMEM with 10% FCS to passage 4 or 5. Cells were then growth-arrested in serum-free media for 24 h and harvested for PCR/western blot or plated on 13 mm coverslips and then growth-arrested for staining and translocation experiments. Identification of each line of cells as smooth muscle was verified by positive staining with anti-smooth muscle a-actin, and anti-calponin antibodies (Santa Cruz Biotechnology, CA, USA). ] was adjusted by mixing the two solutions in the appropriate proportion, as calculated by WEBMAXC software (www.stamford.edu). SU6656, PP2, PP3 and Y27632 were all obtained from Calbiochem (Merck Biosciences Nottingham, UK). PGF 2a (tromethamine salt) was purchased from Biomol (Exeter, UK). All other reagents were obtained from Sigma (Poole, UK) Calbiochem, Invitrogen (Paisley, UK), or Fisher (Loughborough, UK).
Solutions
RNA isolation and reverse transcriptasepolymerase chain reaction
Total RNA was extracted from IPA or PASMC using the Qiagen RNeasy mini kit and TissueLyser (Qiagen, Crawley, UK). RNA was treated with TURBO DNase (Ambion, Austin, TX, USA) to remove any remaining contaminating DNA and then reverse-transcribed in the presence of RNAguard (GE Healthcare, Chalfont St Giles, UK) by using random hexamers and revert-aid reverse transcriptase (Fermentas International, York, UK All PCR primers were supplied by MWG Biotech (Ebersberg, Germany). PCR was carried out using 100 ng of reverse-transcribed RNA, 1Â PCR II buffer, 4 mM MgCl 2 , 2 U Amplitaq Gold (Applied Biosystems, Warrington, UK), 0.5 U Perfect Match (Stratagene Europe, The Netherlands), 0.25 mM dNTPs (Fermentas International, York, UK), and 1.25 mM primer pair in a final volume of 40 mL. PCR cycling conditions were 10 min 958C followed by 4 cycles of 2 min 958C, 10 min 578C, 2 min 728C and then a variable number of cycles of 2 min 958C, 2 min 578C, 2 min 728C (total number of cycles indicated in figure legends). Eighty microlitres of PCR products (reaction equivalent on 20 ng reverse-transcribed RNA) were analysed by electrophoresis on 2.8% agarose gels run in 1Â TAE buffer (National Diagnostics, Yorkshire, UK) with PhiX174 DNA/ HinfI Marker (Fermentas International, York, UK). Gel-purified PCR fragments were sequenced to confirm identity (Geneservice, Medical Solutions plc, UK).
Western blot
IPA segments were treated with PGF 2a (20 mM) , following a 15 min equilibration period in PSS and a 15 min pre-incubation with pharmacological agents where appropriate, gassed with 5% CO 2 / balance air at 378C, prior to snap-freezing. Tissue was homogenized and protein extracted in 50 mL of Tris/SDS sample buffer containing phosphatase inhibitor cocktail I and II (Sigma) and protease inhibitor cocktail I (Sigma). Protein was extracted from PASMC by the same method. Protein extracts (12-15 mL, 10 mg, per lane) were run on SDS/PAGE gels (4-12% gradient, Invitrogen), transferred to nitrocellulose membrane, blocked with 5% skimmed milk for 1 h, probed with primary antibody (1:1000, in Tris-buffered saline with 0.1% skimmed milk) overnight at 48C and then with horseradishperoxidase conjugated anti-IgG secondary antibody (1:5000 in tris-buffered saline with 1% milk) for 1 h at room temperature. For phosphorylation experiments, membranes were first probed with anti-phospho-antibodies, stripped for 1 h (Pierce stripping buffer), re-blocked, and re-probed with corresponding anti-total antibodies. Protein bands were visualized with Supersignal West Femto Maximum Sensitivity Substrate (Pierce, Cramlington, UK) or ECL western blotting detection reagent (Amersham, Bucks, UK) and exposed to photographic film. Rabbit anti-src, rabbit anti-phospho-srcFK (tyr-416), mouse anti-phospho-tyrosine, rabbit anti-myosin light-chain, mouse anti-phospho-myosin light-chain (ser-19), and mouse anti-b-actin antibodies were obtained from Cell Signaling. Sheep anti-MYPT-1, rabbit anti-phospho-MYPT-1 (thr-695: equivalent to thr-697 in rat), and rabbit anti-phospho-MYPT-1 (thr-850: equivalent to thr-855 in rat) antibodies were obtained from Upstate (UK).
Force measurement and a-toxin permeabilization
IPAs were mounted on a Mulvany-Halpern wire myograph (DMT A/S, Aarhus, Denmark), bathed in PSS (gassed with 95% air/5% CO 2 , pH 7.4), and stretched to 90% of the circumference necessary to create an equivalent transmural pressure of 4.4 kPa (30 mmHg). IPAs were equilibrated with three 3 min contractions to 80 mM K þ PSS and then permeabilized with a-toxin as follows. First, arteries were equilibrated in relaxing solution (as mentioned earlier) and then permeabilized by incubation at pCa 6.5 with 60 mg/mL a-toxin until the resulting vasoconstriction reached a plateau. Following re-equilibration with relaxing solution, submaximal vasoconstriction was elicited with pCa 6.9, and then PGF 2a (100 mM) was applied, in the presence of 1 mM GTP to support G-protein activation. All contraction experiments were conducted at 268C and in the presence of 10 mM cyclopiazonic acid to remove the influence of Ca 2þ store release on contraction.
Staining and image analysis
PASMC were treated with 20 mM PGF for 10 min in DMEM at 378C with or without prior application of 30 mM SU6656 for 10 min. Reactions were terminated by addition of paraformaldehyde fixative. For ROCK-2 translocation, fixed cells were permeabilized with Triton-100 and stained overnight with anti-ROCK-2 primary antibody (1:100, Santa Cruz Biotechnology) at 48C following incubation with Alexa Fluor 488-labelled secondary antibody (1:1000, Santa Cruz) for 1 h at room temperature. Specificity of anti-ROCK-2 was confirmed by western blot (single band at 160 kDa). Staining was negative with secondary antibody alone.
Data analysis and statistics
Images of western blot bands of appropriate molecular weights were quantified using Image J software (rsb.info.nih.gov). Band intensity was expressed as a ratio of phospho/total for each protein, and values from each treated sample were normalized to those from control (untreated) samples run on the same gel. Two to three control samples were run on each gel and averaged. Statistical analysis was performed with SigmaStat (Systat software Inc. 
Results
Expression of src family kinases
PCR was performed on mRNA extracts from IPA. All nine src family members were expressed, and the three most abundant are shown in Figure 1A (see Supplementary material online, Figure Si for all nine). A similar expression pattern was obtained from cultured rat PASMC (see Supplementary material online, Figure Sii ). srcFK were also expressed at the protein level. Three bands were visualized, two at 59/60 kDa and one at 54 kDa. These correspond to the three most highly expressed at the mRNA level, src, and the closely related fyn and yes, with expected molecular weights in rat of 60, 60, and 54 kDa, respectively (as calculated from the predicted amino acid sequence at www.bioinformatics.org). Representative blots are shown in Figure 1B . Similar protein expression was obtained from cultured rat PASMC (see Supplementary material online, Figure Sii) . In order to demonstrate full kinase activity, srcFK require auto-phosphorylation at tyr-416. 10 Phospho-srcFK (tyr-416) immunoreactivity was inhibited by the srcFK inhibitor PP2 (at 3 and 30 mM but not at 0.3 mM) but not by the inactive analogue PP3 (30 mM) ( Figure 1B) , indicating in this preparation that 30 mM PP2 is required to substantially inhibit srcFK auto-phosphorylation, and hence srcFK activity.
src family kinases inhibition antagonizes PGF 2a -mediated Ca 21 -sensitization
IPAs were permeabilized with a-toxin and submaximally constricted with pCa clamped at 6.9. This constriction was enhanced approximately three-fold by application of PGF 2a , reaching a maximum at 40-45 min. At this point, the srcFK inhibitors SU6656 and PP2 or the inactive analogue PP3 was applied. These treatments were compared with parallel time controls in which drug was not applied. DMSO vehicle controls (applied in the place of drug) were indistinguishable from time controls (not shown). SU6656 ( Figure 2A ) and PP2 ( Figure 2B ) both caused significant relaxation at 3 and 30 mM, and this was significantly greater than the small degree of spontaneous run-down shown by the time controls. PP3 also caused relaxation at 30 mM, but this was significantly less than for PP2 ( Figure 2C ). SU6656-mediated relaxation was unaffected by de-endothelialization (n ¼ 6) and was similar when SU6656 was applied prior to the PGF 2a (n ¼ 5) as when it was added acutely (see Supplementary material online, Figures Siii and Siv, respectively). The srcFK inhibitors SU6656 and PP2 cannot distinguish between different members of the src family. However src may be distinguished by the manner in which it is modified for insertion into the plasma membrane, a process required for full kinase activity. 8, 20 src is simply myristoylated, whereas other family members, including fyn and yes, are also palmitoylated. 8, 21 We therefore evaluated the effects of the acylation inhibitor 2-bromopalmitate and of ecosapentaenoic acid (EPA, which selectively displaces palmitoylated proteins from the membrane) on PGF 2a -induced Ca 2þ -sensitization. 8, 20, 21 When 100 mM 2-bromopalmitate was applied to a pre-existing PGF 2a -induced contraction, a small additional transient contraction was caused, which was followed by a large sustained relaxation ( Figure 2D) . In contrast to this, 60 mM EPA caused a large sustained additional contraction and no relaxation (288 + 66% increase, P , 0.01 vs. time controls at 90 min, n ¼ 5).
PGF 2a enhances src family kinases auto-phosphorylation and protein tyrosine phosphorylation
In order to test the hypothesis that PGF 2a -mediated contraction was acting via srcFK activation and protein tyrosine phosphorylation, further western blot experiments were performed in PGF 2a -treated IPA with anti-phospho-srcFK (tyr-416) and anti-phospho-tyrosine. As shown in Figure 3A , srcFK phosphorylation at tyr-416 was enhanced by PGF 2a in a time-dependent manner. The two bands analysed (60 and 54 kDa) showed significant peak enhancements at 2-5 min, whereas at 60 kDa, a significant second-phase-sustained enhancement at 30 min was apparent. Several protein bands were visualized with anti-phospho-tyrosine in IPA: a single intense band at 120 kDa, bands at 95 and 75 kDa, and a close collection of bands centred at 65 kDa ( Figure 3B ). This immunoreactivity was enhanced by PGF 2a , significantly inhibited by PP2, but unaffected by PP3 (30 mM). Other fainter bands were present but were not quantified.
PGF 2a mediates Ca 21 -sensitization via MYPT-1 and MLC 20 phosphorylation
Western blot experiments were carried out for MYPT-1 (both phospho-thr-697 and phosho-thr-855) and MLC 20 (phospho-ser-19) in PGF-treated IPA. PGF 2a significantly enhanced phosphorylation of MYPT-1 at both thr-697 ( Figure 4A ) and thr-855 ( Figure 4B ), although this effect was greater at thr-855. As expected, PGF 2a also significantly enhanced ser-19 phosphorylation on MLC 20 ( Figure 4C) . With both MYPT-1 at thr-855 and MLC 20 at ser-19, the Protein expression of src family kinases by western blot analysis of intra-pulmonary artery. Three bands (two at 59/60 kDa, and one at 54 kDa) were visualized with anti-src and by anti-phospho-src family kinases (tyr-416). Phospho-src family kinases (tyr-416) immunoreactivity at 60 and 54 kDa was inhibited by PP2 (3 mM, *P , 0.05, n ¼ 8 rats and 30 mM, P , 0.05, n ¼ 8 rats) but not by PP3 (30 mM, n ¼ 8 rats). Figure 2 Effect of src family kinase inhibitors on PGF 2a -induced contraction in a-toxin-permeabilized intra-pulmonary artery. intra-pulmonary arteries were pre-constricted with pCa6.9 for 30 min, prior to the addition of 100 mM PGF 2a for 40 min (A-C) or 90 min (D). Compared with appropriate time controls (n ¼ 12 arteries), this contraction was significantly relaxed by SU6656 [(A) 3 mM, 28 + 3%, *P , 0.05, n ¼ 8 arteries and 30 mM, 54 + 4%, *P , 0.01, n ¼ 8 arteries] and by PP2 [(B) 3 mM, 25 + 5%, *P , 0.05, n ¼ 8 arteries and 30 mM, 46 + 5%, *P , 0.01, n ¼ 12 arteries]. PP3 also caused relaxation at 30 mM [(C) 28+ 2%, *P , 0.05, n ¼ 12 arteries] but was significantly less effective than PP2 ( †P , 0.05). 2-Bromopalmitate (2-BP) caused a transient contraction (non-significant) followed by significant relaxation [(D) 100 mM, 71 + 4%, *P , 0.01, n ¼ 7 arteries, compared with time controls, n ¼ 7 arteries].
PGF-stimulated increase in phosphorylation peaked at 10 min. This time point was therefore used in subsequent phosphorylation experiments.
MYPT-1 and MLC 20 phosphorylation are sensitive to inhibition of src family kinases and rho-kinase
Basal phosphorylation of MYPT-1 at thr-697 and thr-855 and MLC 20 at ser-19 was not significantly affected by 30 mM SU6656, but was reduced by the rho-kinase inhibitor Y27632 (10 mM) ( Figure 5A-C) . Y27632 was much more effective against MYPT-1 phosphorylation at thr-855 than at thr-697. After 10 min exposure to PGF 2a , phosphorylation of MYPT-1 at thr-697 and thr-855 and MLC 20 at ser-19 was enhanced ( Figure 5D-F ) . This PGF 2a -induced enhancement of MYPT-1 phosphorylation at thr-855 and MLC 20 phosphorylation at ser-19 was nearly abolished by 30 mM SU6656 ( Figure 5E and F) . Y27632 also greatly inhibited the phosphorylation of these two sites. The effects of the two inhibitors when used in combination were however not additive ( Figure 5D-F ).
Interaction between src family kinases and rho-kinase during PGF 2a -mediated Ca
-sensitization
The results shown in Figure 5 suggest that srcFK activation may be part of the same pathway as PGF 2a -induced rho-kinase-mediated phosphorylation of MYPT-1. This was corroborated by further contraction experiments in a-toxin-permeabilized IPA. As expected, 30 mM SU6656 did not have any significant effect on pCa 6.9-induced contraction in the absence of PGF 2a ( Figure 6A) . PP2, PP3, and 2-bromopalmitate were similarly without effect (PP2 and PP3: 30 mM, n ¼ 8, 2-BP: 100 mM, n ¼ 5, not shown). Y27632, however, did relax this contraction, indicative of significant basal rho-kinase activity in the absence of agonist ( Figure 6A ). Y27632 also greatly relaxed the PGF 2a -induced contraction, but this relaxation was not significantly greater when SU6656 was applied simultaneously with Y27632 ( Figure 6B) . The PKC-d selective blocker rottlerin was completely without effect on PGF 2a contraction (see Supplementary material online, Figure Sv) , eliminating the possibility that our results were influenced by inhibition of PKC-d by Y27632, as shown previously by Wilson et al.
22
To examine more closely the interaction between srcFK and rho-kinase during stimulation with PGF 2a , we examined in PASMC the subcellular translocation of rho-kinase, a process that is required for its activation and therefore precedes phosphorylation of MYPT-1. 5 In control cells, the majority of rho-kinase (ROCK-2, the isoform activated by RhoA) antibody staining was localized to the nucleus; with some cytoplasmic staining, but upon stimulation with PGF 2a , most of this translocated to the cytoskeleton. This movement was almost completely reversed by pre-treatment with SU6656 ( Figure 6C ). In the absence of PGF 2a , SU6656 was without effect (not shown). No ROCK-2 was detected in plasma membrane.
Discussion
The results of this study clearly demonstrate the involvement of srcFKs in agonist-induced contraction of the pulmonary artery. Most previous works have relied on the use of non-selective tyrosine kinase inhibitors such as genistein and tyrphostins, which do not distinguish between receptor and non-receptor tyrosine kinases, and have focused on the role of these kinases in Ca 2þ homeostasis (reviewed in Ward et al. 15 ). The few that have addressed the question of Ca 2þ -sensitization have drawn opposing conclusions. For example, in a-toxin-permeabilized rat mesenteric arteries, ET-1-induced contractions were inhibited by tyrphostin-A23, 14 whereas in b-escin-permeabilized guinea-pig mesenteric arteries, direct Ca 2þ -mediated contraction was unaffected by tyrphostin. 11 This discrepancy may be explained by our current findings, since we showed that the srcFK-selective inhibitors SU6656 23 and PP2 24 both selectively inhibited PGF 2a -induced but not direct Ca 2þ -induced contraction in a-toxin-permeabilized rat pulmonary artery and inhibited PGF 2a -mediated but not basal MLC 20 phosphorylation at ser-19, suggesting the involvement of srcFK only during stimulation of G-protein-coupled receptors.
MYPT-1, the regulatory subunit of myosin phosphatase, is an important mediator of changes in contractile force independent of a change in [Ca 2þ ] i (Ca 2þ -sensitization). 2 As has been previously shown for PGF 2a and other agonists in other vascular preparations, 22, 25, 26 we observed that PGF 2a enhanced MYPT-1 phosphorylation at two sites, thr-697 and thr-855 (the rat homologues of thr-696 and thr-850 in humans), but it was principally phosphorylation at thr-855 which was most sensitive to rho-kinase inhibition by Y27632. Although both threonine residues were previously shown to be targets of rho-kinase, 3, 4 our results agree with several other reports that thr-855 or its equivalent in other vascular preparations is the principal target of rhokinase and that thr-697 is phosphorylated basally by another as-yet-unspecified serine/threonine kinase. 22, 25, 26 As with phosphorylation of MLC 20 , the enhancement of MYPT-1 phosphorylation at thr-855 by PGF 2a was inhibited by SU6656 although basal phosphorylation was unaffected. Interestingly, Y27632 nearly abolished the pCa 6.9-induced contractions in IPA as well as the basal MYPT-1 phosphorylation at thr-855 and significantly inhibited MLC 20 phosphorylation, suggesting that there is considerable basal rho-kinase activity in the rat pulmonary artery. In any case, it is stimulated further by the addition of Figure 6 Interaction between src family kinases and rho-kinase activity in PGF 2a -stimulated intra-pulmonary artery and pulmonary artery smooth muscle cells. (A) In intra-pulmonary artery, in the absence of PGF 2a , the pCa6.9 contraction was inhibited by Y27632 (10 mM, *P , 0.001, n ¼ 8, compared with time controls, n ¼ 8 arteries) but not by SU6656 (30 mM, n ¼ 8 arteries). (B) Y27632 also inhibited contraction in the presence of PGF 2a (10 mM, 84 + 2%, *P , 0.001, n ¼ 8 arteries) and this relaxation was unaltered by the additional presence of SU6656 (30 mM, 87 + 2%, *P , 0.001, n ¼ 8 arteries). The effect of SU6656 alone (from Figure 2 ) is included as a comparison. (C) In pulmonary artery smooth muscle cells, PGF 2a triggered translocation of rho-kinase (ROCK-2) immunoreactivity from the nucleus to the cytoskeleton (20 mM, *P , 0.05, n ¼ 6 determinations) and this was prevented by SU6656 (30 mM; *P , 0.05, n ¼ 6 determinations). agonist.
A similar observation was made in U46619-stimulated rat caudal artery. 22 The src family members most likely to be required for the responses described in this study are the highly expressed src and fyn, which have both been previously implicated in smooth muscle contraction, 7, 16 and possibly yes, which is also highly expressed. Unfortunately, existing kinase inhibitors cannot easily distinguish between src, fyn, or yes. However, these kinases do differ in the way that they are post-translationally modified; src is dualmyristoylated, whereas both fyn and yes are also palmitoylated. 8 Previously, using inhibitors of fatty acid acylation and palmitoylation, Nakao et al. 16 suggested that sphingosylphosphorylcholine-induced Ca 2þ -sensitization in porcine coronary artery was mediated specifically by fyn, not src. We, however, found that the non-selective acylation inhibitor 2-bromopalmitate, but not the selective palmitoylation inhibitor EPA, 21 inhibited PGF 2a -mediated Ca 2þ -sensitization. Accordingly, but bearing in mind that other important membrane-signalling proteins are also myristoylated and palmitoylated, 27 we may tentatively suggest that it is specifically src and not fyn or yes which is the srcFK involved in PGF 2a -mediated Ca 2þ -sensitization in rat IPA. The additional contractions caused by 2-bromopalmitate and EPA are presumably due to further actions of these drugs, independent of PGF 2a stimulation or srcFK activity.
The question arises as to whether srcFK activation in response to PGF 2a is upstream of rho/rho-kinase or enhances Ca 2þ -sensitivity through a separate pathway. The actions of SU6656 and Y27632 were not additive with respect to both inhibition of PGF 2a -induced MYPT-1 and MLC 20 phosphorylation and inhibition of the associated PGF 2a -induced contraction, suggesting that srcFK and rho-kinase may be part of the same pathway. In order to test this hypothesis, we examined translocation of rho-kinase in PASMC, a process that is important for the activation of the kinase. 5 In control cells, rho-kinase staining was concentrated in the nucleus, as has been shown previously, 28 but upon PGF 2a treatment, it translocated to the cytoskeleton. Importantly, this movement was reversed by pre-treatment with SU6656, indicating that the movement of rho-kinase in response to stimulation by PGF 2a was likely to be mediated by srcFK. In contrast to the study of Nakao et al., 16 we found no evidence for the presence of rho-kinase at the plasma membrane, either in control or in stimulated cells.
PGF 2a mediates Ca 2þ -sensitization via the TP receptor, 29 which is coupled to Ga q/11 . 30 How this coupling results in activation of srcFK and/or rho/rho-kinase is unclear. For full kinase activity, srcFK require auto-phosphorylation at tyr-416 10 and we showed that this is enhanced by PGF 2a , indicating that srcFK activity was increased. Src activation often goes hand in hand with focal adhesion kinase (FAK) which is activated by src.
31,32 FAK may be the 120 kDa protein whose tyrosine phosphorylation in the current study was enhanced by PGF 2a and inhibited by PP2. A wellestablished connection between G-protein-linked receptors such as the TP prostenoid receptor (which is activated by PGF 2a 29 ) and mitogenic signalling involves src-dependent transactivation of the EGF-receptor tyrosine kinase. 33 This mechanism also involves Ga i , which is known to activate src by direct coupling. 34 Studies with the tyrosine phosphatise inhibitor vanadate have suggested that RhoA translocation is stimulated by as-yet-unspecified tyrosine phosphorylation. 35 Furthermore, a pathway for tyrosine kinase-dependent modulation of rho activation has been suggested: active rho requires GTP, and it acquires this from rho-specific RhoGEF. 6 Two RhoGEFs in native smooth muscle that may enhance RhoA activation by Ga q or Ga 12/ 13 are leukaemia-associated RhoGEF (LARG) and PDZ-RhoGEF, 26, 36 and LARG is indeed activated by tyrosine phosphorylation. 37 In conclusion, we have shown for the first time that agonist-mediated, rho-kinase-dependent Ca 2þ -sensitization but not basal rho-kinase activity in rat pulmonary artery requires srcFK activity. This has implications for the regulation of rho and rho-kinase-dependent vascular tone and vascular remodelling in health and disease. The precise mechanism(s) by which G-protein-linked receptors couple to srcFK and subsequent rho-kinase activation remain to be determined.
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